Abstract
We report on 12 patients with chronic granulomatous disease transplanted with hematopoietic stem cells from matched unrelated (n = 9) or matched sibling donors (n = 3). The most common infectious complication was pulmonary aspergillosis, which nine patients had previously developed. Only 5 of 12 individuals had normal lung function prior to transplantation. At a mean follow-up of 53 months 9 of the 12 patients are alive including 7 of 9 following matched unrelated donor (MUD) transplantation. One patient died from ARDS, another from systemic BK virus infection, the third from complications of chronic graft-versus-host disease. Seven of nine surviving patients have normal lung function now. HSCT from a MUD is an option worth considering when no matched family donor is available. Restricted lung function prior to HSCT does not appear to be a limiting factor for such treatment.
MeSH terms
-
Adolescent
-
Busulfan / administration & dosage
-
Busulfan / therapeutic use
-
Child
-
Child, Preschool
-
Chimerism
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / therapeutic use
-
Follow-Up Studies
-
Granulomatous Disease, Chronic / immunology
-
Granulomatous Disease, Chronic / mortality
-
Granulomatous Disease, Chronic / surgery*
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Hematopoietic Stem Cell Transplantation / methods*
-
Histocompatibility / immunology
-
Humans
-
Kaplan-Meier Estimate
-
Male
-
Melphalan / administration & dosage
-
Melphalan / therapeutic use
-
Postoperative Complications / immunology
-
Postoperative Complications / mortality
-
Pulmonary Aspergillosis / etiology
-
Pulmonary Aspergillosis / mortality
-
Retrospective Studies
-
Treatment Outcome
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives
-
Vidarabine / therapeutic use
-
Young Adult
Substances
-
Cyclophosphamide
-
Vidarabine
-
Busulfan
-
fludarabine
-
Melphalan